




## Rasagiline

Revised: October 19, 2020.

CASRN: 136236-51-6



## Drug Levels and Effects

### Summary of Use during Lactation

No clinical use of rasagiline during breastfeeding has been reported. Rasagiline might reduce serum prolactin and interfere with milk production. An alternate drug may be preferred, especially while nursing a newborn or preterm infant.

### Drug Levels

*Maternal Levels.* Relevant published information was not found as of the revision date.

*Infant Levels.* Relevant published information was not found as of the revision date.

**Disclaimer:** Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

**Attribution Statement:** LactMed is a registered trademark of the U.S. Department of Health and Human Services.

## Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

## Effects on Lactation and Breastmilk

Animal studies show that rasagiline reduces serum prolactin. The clinical relevance of these findings in nursing mothers is not known. The prolactin level in a mother with established lactation may not affect her ability to breastfeed.

## Alternate Drugs to Consider

Selegiline

## Substance Identification

### Substance Name

Rasagiline

### CAS Registry Number

136236-51-6

### Drug Class

Breast Feeding

Lactation

Antiparkinson Agents

Monoamine Oxidase Inhibitors

Neuroprotective Agents